D2-40 Immunreactivity In Colon Adenocarcinomas

Yet, due to the fact that there are few studies in literature on immunoreactivity withD2-40 in tumor cells in colon adenocarcinomas, we believe that further studies are needed inthis subject

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Aim: In the present study, the relationship between D2-40 immunoreactivity and tumor grade,clinic phase and lymph node metastase in colon adenocarcinomas were examined.Method: Sixty cases diagnosed with colon adenocarcinoma in our department between 2002and 2009 were included in the study.

📊

Key Findings & Data:Sections from appropriate paraffin blocks belonging tothe cases were examined by D2-40 antibody immunohistochemical method.Findings: On the immunohistochemical examination, positive immunoreactivity with D2-40was found in 18 of 60 cases (30%).

💡

Conclusion & Impact:Yet, due to the fact that there are few studies in literature on immunoreactivity withD2-40 in tumor cells in colon adenocarcinomas, we believe that further studies are needed inthis subject

🔬Design:Research Article

📍Scope:2009 Verileri

⚙️Variables:Kolon adenokarsinomu · D2-40 · prognoz

Abstract

Aim: In the present study, the relationship between D2-40 immunoreactivity and tumor grade,clinic phase and lymph node metastase in colon adenocarcinomas were examined.Method: Sixty cases diagnosed with colon adenocarcinoma in our department between 2002and 2009 were included in the study. Sections from appropriate paraffin blocks belonging tothe cases were examined by D2-40 antibody immunohistochemical method.Findings: On the immunohistochemical examination, positive immunoreactivity with D2-40was found in 18 of 60 cases (30%). In the statistical analysis, no significant correlation wasdetermined between histologic grade (p:0,78), clinic phase (p:0,91), lymph node metastasis(p:0,56) and D2-40 immunoreactivity.Conclusion: No correlation was found between immunoreactivity with D2-40 and prognosticparameters. Yet, due to the fact that there are few studies in literature on immunoreactivity withD2-40 in tumor cells in colon adenocarcinomas, we believe that further studies are needed inthis subject

Özet

Amaç: Çalışmamızda, kolon adenokarsinomlarında D2-40 immünreaktivitesi ile tümör grade’i,klinik evre ve lenf nodu metastazı arasındaki ilişki araştırılmıştır.Yöntem: Bu çalışmada 2002-2009 yılları arasında kliniğimizde kolon adenokarsinomu tanısıkonulan 60 olgu incelemeye alındı. Bu olgulara ait uygun parafin bloklardan yapılan kesitlereD2-40 antikoru immünohistokimyasal yöntemle çalışılmıştır.Bulgular: İmmünohistokimyasal inceleme sonucunda 60 olgunun 18’inde (%30) D2-40 ilepozitif immünreaktivite saptanmıştır. Yapılan istatistiksel analiz sonucunda histolojik grade(p:0,78), klinik evre (p:0,91) ve lenf nodu metastazı (p:0,56) ile D2-40 immünreaktivitesiarasında anlamlı bir ilişki izlenmemiştir.Sonuç: D2-40 immünreaktivitesi ile incelediğimiz prognostik parametreler arasında korelasyonbulunmamıştır. Ancak; literatürde kolon adenokarsinomlarında tümör hücrelerindekiimmünreaktiviteyi araştıran az sayıda çalışma olması nedeni ile bu konuda ileri çalışmalaraihtiyaç olduğu kanaatindeyiz

Keywords

Kolon adenokarsinomu D2-40 prognoz Colon adenocarcinomas prognose

🔖

Cite This Article

ÖZARDALI, H. İ., YILDIZ, F., TERZİ, A., ÖZGÖNÜL, A., BİTİREN, M., YILDIRIM, L., METİNEREN, M. H., GÜLDÜR, M. E. (2011). D2-40 Immunreactivity In Colon Adenocarcinomas. Düzce Tıp Fakültesi Dergisi, Cilt: 13 - Sayı: 2, 1–5. https://ajindex.com/articles/420486

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Liu C, Crawford JM: The Gastrointestinal Tract. In Kumar V, Abbas AK, Fausto N (eds): Robbins Pathologic Basis of Diseases. Philadelphia W. B. Saunders Company. pp: 828– 870, 2005. Aykan NF: Kolon Kanseri. Türkiye Klinikleri J Med Oncol- Special Topics. 1(3): 1–9, 2008 Rosai J; Gastrointestinal Tract In Rosai J. Rosai and Ackerman’s Surgical Pathology. Vol I. New York. Elsevier Inc. pp: 776–855, 2004
Erarslan E, Türkay C: Kolorektal Kanser Etyolojisi ve Predispozan Faktörler. Güncel Gastroenteroloji. 11(1): 19–26, 2007
Banner BF, Whitehouse R, Baker SP, Swanson RS: Tumor angiogenesis in stage II colorectal carcinoma association with survival. Am J Clin Pathol. 109: 733-737, 1998
Deniz H, Kibar Y, Guldur ME, Bakir K: Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract. 205(11): 749-752, 2009
Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, et al: Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol. 35(6): 342-347, 2007
Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF: The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol. 34 (12): 801-806, 2006
Levy G, Finkelstein A, McNiff JM: Immunohistochemical techniques to compare primary vs. metastatic mucinous carcinoma of the skin. J Cutan Pathol. 37 (4): 411– 415, 2009
Lin X, Lindner JL, Silverman JF, Liu Y: Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically Immunohistochem Mol Morphol. 16(5): 453-458, 2008
Nakamura Y, Kanemura Y, Yamada T,Sugita Y, et al: D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol. 19(7): 974-985, 2006 distinct entities. Appl Browning L, Bailey D, Parker A: D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol. 61(3): 293-296, 2008
Kadota K, Huang CL, Liu D, Nakashima N, Yokomise H, et al: The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 44(7): 1057-1067, 2008
Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, et al: Comparison of risk factors for colon and rectal cancer. Int J Cancer. 111(5): 809-810, 2004
Gomaa AH, Yaar M, Bhawan J: Cutaneous immunoreactivity of D2–40 antibody beyond